Kuda dalje sa terapijskim monitoringom antiepileptika?

REFERENCES

André P, Novy J, Decosterd LA, Buclin T, Rothuizen LE. Thera-peutic Drug Monitoring of Antiepileptic Drugs in the 21st Century. Epileptologie 2015; 32: 78–84.

Glauser TA, Pippenger CE. Controversies in Blood-level Moni-toring: Reexamining Its Role in the Treatment of Epilepsy. Epilepsia 2000; 41(Suppl 8): S6–15.

French JA, Gazzola DM. New generation antiepileptic drugs: What do they offer in terms of improved tolerability and safe-ty. Ther Adv Drug Saf 2011; 2(4): 141–58.

Mula M. Third generation antiepileptic drug monotherapies in adults with epilepsy. Expert Rev Neurother 2016; 16(9): 1087–92.

Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, et al. Antiepileptic drugs: Best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008; 49(7): 1239–76.

Jannuzzi G, Cian P, Fattore C, Gatti G, Bartoli A, Monaco F, et al. A multicenter randomized controlled trial on the clinical impact of therapeutic drug monitoring in patients with newly diagnosed epilepsy. The Italian TDM Study Group in Epilepsy. Epilepsia 2000; 41(2): 222–30.

Stepanova D, Beran RG. Measurement of levetiracetam drug le-vels to assist with seizure control and monitoring of drug inte-ractions with other anti-epileptic medications (AEMs). Seizure 2014; 23(5): 371–6.

Fröscher W, Keller F, Vogt H, Krämer G. Prospective study on concentration-efficacy and concentration-toxicity: Cor-relations with lamotrigine serum levels. Epileptic Disord 2002; 4(1): 49–56.

Johannessen SI, Battino D, Berry DJ, Bialer M, Krämer G, Tomson T, et al. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther Drug Monit 2003; 25(3): 347–63.

Klein P, Tyrlikova I, Brazdil M, Rektor I. Brivaracetam for the treatment of epilepsy. Expert Opin Pharmacother 2016; 17(2): 283–95.

Jansen AJ, Hunfeld NG, Bommel J, Koch BC, Gelder T. Therapeutic drug monitoring of free fraction valproic acid in patients with hypoalbuminaemia. Neth J Med 2012; 70(7): 329.

Walson PD. Practical problems of therapeutic drug monitoring of anticonvulsants. Brain Dev 1985; 7(2): 116–21.

Eadie MJ. Indications for plasma drug monitoring in patients with epilepsy. Implications for reducing costs. Pharmacoeco-nomics 1997; 11(4): 343–9.

Schmidt D, Haenel F. Therapeutic plasma levels of phenytoin, phenobarbital, and carbamazepine: Individual variation in relation to seizure frequency and type. Neurology 1984; 34(9): 1252–5.

Babaei A, Eslamai MH. Evaluation of therapeutic drug level monitoring of phenobarbital, phenytoin and carbamazepine in Iranian epileptic patients. Int J Clin Pharmacol Ther 2007; 45(2): 121–5.

Perucca E. Free Level Monitoring of Antiepileptic Drugs Clini-cal Usefulness and Case Studies. Clin Pharmacokinet 1984; 9(Suppl 1): 71–8.

Krasowski MD, Penrod LE. Clinical decision support of thera-peutic drug monitoring of phenytoin: Measured versus ad-justed phenytoin plasma concentrations. BMC Med Inform Decis Mak 2012;12: 7.

Bentué-Ferrer D, Tribut O, Verdier MC. Le groupe Suivi Théra-peutique Pharmacologique de la Société Française de Pharma-cologie et de Thérapeutique. Therapeutic drug monitoring of lamotrigine. Therapie 2010; 65(1): 39–46. (French)

Battino D, Croci D, Granata T, Estienne M, Pisani F, Avanzini G. Lamotrigine plasma concentrations in children and adults: In-fluence of age and associated therapy. Ther Drug Monit 1997; 19(6): 620–7.

Fröscher W, Schier KR, Hoffmann M, Meyer A, May TW, Rambeck B, et al. Topiramate: A prospective study on the relationship between concentration, dosage and adverse events in epileptic patients on combination therapy. Epileptic Disord 2005; 7(3): 237–48.

Ferrari AR, Guerrini R, Gatti G, Alessandrì MG, Bonanni P, Perucca E. Influence of dosage, age, and co-medication on plasma topiramate concentrations in children and adults with severe epilepsy and preliminary observations on correlations with clinical response. Ther Drug Monit 2003; 25(6): 700–8.

Bentué-Ferrer D, Tribut O, Verdier MC. Le groupe Suivi Théra-peutique Pharmacologique de la Société Française de Pharma-cologie et de Thérapeutique. Therapeutic drug monitoring of tiagabine. Therapie 2010; 65(1): 51–5. (French)

Bentué-Ferrer D, Tribut O, Verdier MC. Le groupe Suivi Théra-peutique Pharmacologique de la Société Française de Pharma-cologie et de Thérapeutique. Therapeutic drug monitoring of pregabaline. Therapie 2010; 65(1): 47–9. (French)

Bentué-Ferrer D, Tribut O, Verdier MC. Le groupe Suivi Théra-peutique Pharmacologique de la Société Française de Pharma-cologie et de Thérapeutique. Therapeutic drug monitoring of vigabatrin. Therapie 2010; 65(1): 23–7. (French)

Jacob S, Nair AB. An Updated Overview on Therapeutic Drug Monitoring of Recent Antiepileptic Drugs. Drugs R D 2016; 16(4): 303–16.

Johannessen Landmark C, Beiske G, Baftiu A, Burns ML, Johannessen SI. Experience from therapeutic drug monitoring and gender aspects of gabapentin and pregabalin in clinical practice. Seizure 2015; 28: 88–91.

Tribut O, Bentué-Ferrer D, Verdier MC. Le groupe Suivi Théra-peutique Pharmacologique de la Société Française de Pharma-cologie et de Thérapeutique. Therapeutic drug monitoring of felbamate. Therapie 2010; 65(1): 35–8. (French)

Luszczki JJ. Third-generation antiepileptic drugs: Mechanisms of action, pharmacokinetics and interactions. Pharmacol Rep 2009; 61(2): 197–216.

Svendsen T, Brodtkorb E, Reimers A, Molden E, Sætre E, Johannessen SI, et al. Pharmacokinetic variability, efficacy and tolerability of eslicarbazepine acetate. A national approach to the evaluation of therapeutic drug monitoring data and clinicaloutcome. Epilepsy Res 2017; 129: 125–31.

Svendsen T, Brodtkorb E, Baftiu A, Burns ML, Johannessen SI, Jo-hannessen LC. Therapeutic Drug Monitoring of Lacosamide in Norway: Focus on Pharmacokinetic Variability, Efficacy and Tolerability. Neurochem Res 2017; 42(7): 2077–83.

Franco V, Marchiselli R, Fattore C, Tartara E, De Sarro G, Russo E, et al. Development and Validation of an HPLC-UV Assay for the Therapeutic Monitoring of the New Antiepileptic Drug Perampanel in Human Plasma. Ther Drug Monit 2016; 38(6): 744–50.

Baldelli S, Cattaneo D, Giodini L, Baietto L, Di Perri G, Avolio AD, Clementi E. Development and validation of a HPLC-UV method for the quantification of antiepileptic drugs in dried plasma spots. Clin Chem Lab Med 2015; 53(3): 435–44.

Dupont S, Biraben A, Lavernhe G, Marquet T, Allaf B. Manage-ment and monitoring of patients treated with zonisamide: The OZONE study. Epileptic Disord 2013; 15(3): 278–88.

May TW, Boor R, Rambeck B, Jürgens U, Korn-Merker E, Brandt C. Serum concentrations of rufinamide in children and adults with epilepsy: The influence of dose, age, and comedication. Ther Drug Monit 2011; 33(2): 214–21.

Goldenberg MM. Overview of drugs used for epilepsy and sei-zures: Etiology, diagnosis, and treatment. Pharm Ther 2010; 35(7): 392–415.

Greenberg RG, Melloni C, Wu H, Gonzalez D, Ku L, Hill KD, et al. Therapeutic Index Estimation of Antiepileptic Drugs: A Systematic Literature Review Approach. Clin Neuropharmacol 2016; 39(5): 232–40.

Melten JW, Wittebrood AJ, Willems HJ, Faber GH, Wemer J, Faber DB. Comparison of equilibrium dialysis, ultrafiltration, and gel permeation chromatography for the determination of free fractions of phenobarbital and phenytoin. J Pharm Sci 1985; 74(6): 692–4.

Briscoe SE, McWhinney BC, Lipman J, Roberts JA, Ungerer JP. A method for determining the free (unbound) concentration of ten beta-lactam antibiotics in human plasma using high per-formance liquid chromatography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci 2012; 907: 178–84.

Milovanović B, Tomović D, Janković SM, Grubor I, Nikolić L, Nikolić M, et al. Factors Influencing the Fear of Needles among Students of Medicine and Pharmacy. Acta Facult Med Naiss 2017; 34(2): 147–58.

Dwivedi R, Singh M, Kaleekal T, Gupta YK, Tripathi M. Concen-tration of antiepileptic drugs in persons with epilepsy: A com-parative study in serum and saliva. Int J Neurosci 2016; 126(11): 972–8.

Miles MV, Tennison MB, Greenwood RS. Intraindividual variability of carbamazepine, phenobarbital, and phenytoin concentrations in saliva. Ther Drug Monit 1991; 13(2): 166–71.

Dwivedi R, Gupta YK, Singh M, Joshi R, Tiwari P, Kaleekal T, et al. Correlation of saliva and serum free valproic acid concentrations in persons with epilepsy. Seizure 2015; 25: 187–90.

Patsalos PN, Berry DJ. Therapeutic drug monitoring of antiepi-leptic drugs by use of saliva. Ther Drug Monit 2013; 35(1): 4–29.

Pennell PB, Peng L, Newport DJ, Ritchie JC, Koganti A, Holley DK, et al. Lamotrigine in pregnancy: Clearance, therapeutic drug monitoring, and seizure frequency. Neurology 2008; 70(22 Pt 2): 2130–6.

Benetello P, Furlanut M, Baraldo M, Tonon A, Furlanut M. Thera-peutic drug monitoring of lamotrigine in patients suffering from resistant partial seizures. Eur Neurol 2002; 48(4): 200–3.

Charfi R, Lakhal M, Klouz A, Trabelsi S, Salouage I. Therapeutic Drug Monitoring of Valproic Acid in Children: A Prospective Study of The Effect of The Compliance and The Economic Level on the Trough Plasmatic Concentrations and Epileptic Seizures. Therapie 2015; 70(5): 415–24. (French)

Pippenger CE. Therapeutic drug monitoring assay development to improve efficacy and safety. Epilepsy Res 2006; 68(1): 60–3.

Sharma S, Joshi S, Mukherji S, Bala K, Tripathi CB. Therapeutic Drug Monitoring: Appropriateness and Clinical Utility in Neuropsychiatry Practice. Am J Ther 2009; 16(1): 11–6.

Beghi E, Trevisan D, Tognoni G. Use of plasma levels for antiepileptic drug monitoring in clinical practice. Gruppo Collaborativo per lo Studio dell'Epilessia. Ital J Neurol Sci 1992; 13(1): 59–65.

Sanavio B, Krol S. On the Slow Diffusion of Point-of-Care Sys-tems in Therapeutic Drug Monitoring. Front Bioeng Biotech-nol 2015; 3: 20.

Meneghello A, Tartaggia S, Alvau MD, Polo F, Toffoli G. Biosensing Technologies for Therapeutic Drug Monitoring. Curr Med Chem 2017 Jul 20. doi: 10.2174/0929867324666170720101736. (In Press)

Franco V, French JA, Perucca E. Challenges in the clinical devel-opment of new antiepileptic drugs. Pharmacol Res 2016; 103: 95–104.